Loading company…
MimeCure develops therapies for chronic lung diseases, including IPF and COPD.
Founded in 2024 by Dr. Luke van der Koog and Prof. Erik Frijlink, MimeCure is based in the Netherlands and develops therapies for chronic lung diseases. Its MC002 therapy uses a naturally occurring protein to promote lung tissue repair in patients with IPF and COPD. The company raised EUR 3 million in a round led by Addington Investment Group, with participation from Apsara Investments, in May 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in